Orthologous CRISPR-Cas9 enzymes for combinatorial genetic screens

Nature Biotechnology

Volumn 36, Issue 2, 2018, Pages 179-189

  Najm, Fadi J ^a,b   Strand, Christine ^a   Donovan, Katherine F ^a   Hegde, Mudra ^a   Sanson, Kendall R ^a   Vaimberg, Emma W ^a   Sullender, Meagan E ^a   Hartenian, Ella ^a   Kalani, Zohra ^a   Fusi, Nicolo ^c   Listgarten, Jennifer ^c   Younger, Scott T ^a   Bernstein, Bradley E ^a,b   Root, David E ^a   Doench, John G ^a  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MICROSOFT RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA; CLONE CELLS; COMPLEX NETWORKS; ENZYMES; GENETIC ENGINEERING; LEARNING SYSTEMS;

COMBINATORIAL SCREENINGS; GENETIC INTERACTION; GENETIC SCREENING; LENTIVIRAL VECTOR; MULTIPLE CELL TYPES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; TRANSCRIPTIONAL ACTIVATIONS;

GENES;

CASPASE; LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; RNA; SINGLE GUIDE RNA; UNCLASSIFIED DRUG; GUIDE RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE;

APOPTOSIS; ARTICLE; CLONING VECTOR; COMBINATORIAL GENETIC SCREENING; CRISPR-CAS9 SYSTEM; GENE INTERACTION; GENE TARGETING; GENETIC SCREENING; KNOCKOUT GENE; MACHINE LEARNING; PHENOTYPE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; TRANSCRIPTION INITIATION; CRISPR CAS SYSTEM; EPISTASIS; GENE KNOCKOUT; GENETICS; HUMAN; SIGNAL TRANSDUCTION;

APOPTOSIS; CRISPR-CAS SYSTEMS; EPISTASIS, GENETIC; GENE KNOCKOUT TECHNIQUES; GENE TARGETING; GENETIC TESTING; HUMANS; MACHINE LEARNING; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; RNA, GUIDE; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85041474301     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.4048     Document Type: Article

References (53)

1. Roguev, A. et al. Quantitative genetic-interaction mapping in mammalian cells. Nat. Methods 10, 432-437 (2013).
2. Horn, T. et al. Mapping of signaling networks through synthetic genetic interaction analysis by RNAi. Nat. Methods 8, 341-346 (2011).
3. Tong, A. H. Y. et al. Global mapping of the yeast genetic interaction network. Science 303, 808-813 (2004).
4. Costanzo, M. et al. A global genetic interaction network maps a wiring diagram of cellular function. Science 353, aaf1420 (2016).
5. Bassik, M. C. et al. A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility. Cell 152, 909-922 (2013).
6. Wong, A. S. L. et al. Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM. Proc. Natl. Acad. Sci. USA 113, 2544-2549 (2016).
7. Shen, J. P. et al. Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions. Nat. Methods 14, 573-576 (2017).
8. Han, K. et al. Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nat. Biotechnol. 35, 463-474 (2017).
9. ter Brake, O. et al. Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol. Ther. 16, 557-564 (2008).
10. Vidigal, J. A. & Ventura, A. Rapid and efficient one-step generation of paired gRNA CRISPR-Cas9 libraries. Nat. Commun. 6, 8083 (2015).
11. Adamson, B. et al. A multiplexed single-cell CRISPR screening platform enables systematic dissection of the unfolded protein response. Cell 167, 1867-1882. e21 (2016).
12. Zetsche, B. et al. Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array. Nat. Biotechnol. 35, 31-34 (2017).
13. McIntyre, G. J., Arndt, A. J., Gillespie, K. M., Mak, W. M. & Fanning, G. C. A comparison of multiple shRNA expression methods for combinatorial RNAi. Genet. Vaccines Ther. 9, 9 (2011).
14. Stockman, V. B. et al. A high-throughput strategy for dissecting mammalian genetic interactions. PLoS One 11, e0167617-e13 (2016).
15. Gilbert, L. A. et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159, 647-661 (2014).
16. Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184-191 (2016).
17. Zhu, S. et al. Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library. Nat. Biotechnol. 34, 1279-1286 (2016).
18. Doench, J. G. et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat. Biotechnol. 32, 1262-1267 (2014).
19. Ran, F. A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186-191 (2015).
20. Friedland, A. E. et al. Characterization of Staphylococcus aureus Cas9: A smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications. Genome Biol. 16, 257 (2015).
21. Hanzlikova, H., Gittens, W., Krejcikova, K., Zeng, Z. & Caldecott, K. W. Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin. Nucleic Acids Res. 45, 2546-2557 (2017).
22. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
23. van Delft, M. F. et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389-399 (2006).
24. Sun, C. & Bernards, R. Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends Biochem. Sci. 39, 465-474 (2014).
25. Buscà, R., Pouysségur, J. & Lenormand, P. ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy Front. Cell Dev. Biol. 4, 53 (2016).
26. Uzgare, A. R. & Isaacs, J. T. Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res. 64, 6190-6199 (2004).
27. Srivas, R. et al. A network of conserved synthetic lethal interactions for exploration of precision cancer therapy. Mol. Cell 63, 514-525 (2016).
28. Hart, T. et al. High-resolution CRISPR screens reveal fitness genes and genotypespecific cancer liabilities. Cell 163, 1515-1526 (2015).
29. Chaudhuri, L. et al. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. Haematologica 99, 688-696 (2014).
30. Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202-208 (2013).
31. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681 (2005).
32. Leverson, J. D. et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci. Transl. Med. 7, 279ra40 (2015).
33. Lessene, G. et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat. Chem. Biol. 9, 390-397 (2013).
34. Kotschy, A. et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538, 477-482 (2016).
35. Dummler, B. et al. Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol. Cell. Biol. 26, 8042-8051 (2006).
36. Nitulescu, G. M. et al. Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review). Int. J. Oncol. 48, 869-885 (2016).
37. Stordal, B. et al. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol. Oncol. 7, 567-579 (2013).
38. Helleday, T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol. Oncol. 5, 387-393 (2011).
39. Rooswinkel, R. W. et al. Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity. Blood 123, 2806-2815 (2014).
40. Cowling, V. & Downward, J. Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway: Absolute requirement for removal of caspase-6 prodomain. Cell Death Differ. 9, 1046-1056 (2002).
41. Kroemer, G., Galluzzi, L. & Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87, 99-163 (2007).
42. Li, P. et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91, 479-489 (1997).
43. Ma, S. B. et al. Bax targets mitochondria by distinct mechanisms before or during apoptotic cell death: A requirement for VDAC2 or Bak for efficient Bax apoptotic function. Cell Death Differ. 21, 1925-1935 (2014).
44. Sarosiek, K. A. et al. BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol. Cell 51, 751-765 (2013).
45. Chavez, A. et al. Highly efficient Cas9-mediated transcriptional programming. Nat. Methods 12, 326-328 (2015).
46. Rotem, A. et al. Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation. Proc. Natl. Acad. Sci. USA 112, 5708-5713 (2015).
47. Miura, Y. et al. Susceptibility to killer T cells of gastric cancer cells enhanced by Mitomycin-C involves induction of ATBF1 and activation of p21 (Waf1/Cip1) promoter. Microbiol. Immunol. 48, 137-145 (2004).
48. Wong, C. C. et al. Inactivating CUX1 mutations promote tumorigenesis. Nat. Genet. 46, 33-38 (2014).
49. Faraonio, R. et al. p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J. Biol. Chem. 281, 39776-39784 (2006).
50. Gao, Y. et al. Complex transcriptional modulation with orthogonal and inducible dCas9 regulators. Nat. Methods 13, 1043-1049 (2016).
51. Kleinstiver, B. P. et al. Broadening the targeting range of Staphylococcus aureus CRISPRCas9 by modifying PAM recognition. Nat. Biotechnol. 33, 1293-1298 (2015).
52. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
53. Forbes, S. A. et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 45, D1, D777-D783 (2017).